THE IMPORTANCE OF ENDOTHELIAL GLYCOCALYX AND ITS MARKERS IN EARLY DIAGNOSIS OF RENAL DYSFUNCTION IN CHRONIC HEART FAILURE
Article Sidebar
Main Article Content
Abstract
Chronic heart failure (CHF) is a multifactorial clinical syndrome characterized by high morbidity and mortality, frequently accompanied by renal impairment that progresses to cardiorenal syndrome. Recent studies have demonstrated that endothelial glycocalyx (EG) dysfunction plays a pivotal role in worsening renal function in CHF. Elevated serum concentrations of EG biomarkers — such as syndecan-1, heparan sulfate, and hyaluronic acid—are strongly associated with microalbuminuria, systolic dysfunction, and reduced glomerular filtration rate. Since conventional markers of renal dysfunction, including creatinine and cystatin-C, typically change only at advanced stages, the detection of EG-related factors alongside them may enable earlier identification of renal reserve decline and interstitial fibrosis. This, in turn, could support timely therapeutic interventions and improve outcomes in patients with CHF..
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1.Ando J. et al., American Journal of Cardiology, 2022; 184: 20–28. doi:10.1016/j.amjcard.2022.02.017.
2.Becker B.F., et al. Endothelial glycocalyx and chronic organ dysfunction. Basic Res Cardiol. 2021;116(1):15.
3. Brown N.J., Vaughan D.E. Angiotensin-converting enzyme inhibitors and endothelial protection in heart failure. J Clin Invest. 2022;132(8):e152345.
4.Butler J., Diakonova M. Nitric oxide and heart failure: Pathophysiological roles. Nat Rev Cardiol. 2023;20(2):135–150.
5. Chappell D., Pall G.S., Kreutziger J. Hyaluronan as an indicator of endothelial injury in cardiovascular disorders. Crit Care. 2022;26(1):185.
6. Chen M., Geng X., Zhao J. Endothelial glycocalyx degradation correlates with acute kidney injury in decompensated heart failure. Kidney Int Rep. 2022;7(5):1152–1161.
7.Clementi A., et al. Prognostic Role of Endothelial Dysfunction Biomarkers in Cardiorenal Syndrome. Clin Chim Acta. 2022;530:1–9.
8. Esmon C.T., Johansson P.I., Chappell D. The endothelial glycocalyx: possible therapeutic target in cardiovascular disorders. Curr Opin Hematol. 2021;28(5):333–339.
9. Franchi F., Scevola E., Zucchetti G. Glycocalyx biomarkers and prognosis in cardiovascular diseases: a systematic review. Eur J Intern Med. 2023;112:10–20.
10. Gao Y., Sun S., Li X. Heparan sulfate fragments as sensitive biomarkers of microvascular injury in kidney disease. Kidney Int. 2022;102(2):321–330.
11. Garside H., Griffiths R., Bailey J., Webb A. J. S., Williamson C., Duchen M. R. (2021). Endothelial glycocalyx degradation in chronic heart failure and its correlation with renal dysfunction biomarkers. Cardiovascular Research, 117(5), 1225–1238. https://doi.org/10.1093/cvr/cvaa328.
12. Liu Y., Zhang Z., Wang R. Serum syndecan-1 predicts early renal impairment in chronic heart failure patients. J Card Fail. 2021;27(10):1036–1044.
13. Matsuzawa Y., Takamura T., Sakamoto K. et al. "Circulating Components of the Endothelial Glycocalyx Predict Mortality in Patients With Decompensated Heart Failure." American Journal of Cardiology. 2022;180:110–117. doi: 10.1016/j.amjcard.2022.03.039. 14.McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Bohm M., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
15. Meijers WC, van der Velde AR, Pascual-Figal DA, et al. Fibrosis Marker Syndecan 1 and Outcome in Patients With Heart Failure With Reduced and Preserved Ejection Fraction. Circ Heart Fail. 2014;7(3):457–462. doi:10.1161/CIRCHEARTFAILURE.113.000846.
16. Ronco C., et al. Cardiorenal syndrome: the cardio-kidney network in heart failure. Nat Rev Nephrol. 2021;17(3):137–155.
17. Satchell S.C., Mathieson P.W. TNF-α-mediated glycocalyx shedding in renal microvasculature. Front Cell Dev Biol. 2023;11:112344.
18. Tarbell J.M., et al. The endothelial glycocalyx as a regulator of blood flow. Am J Physiol Heart Circ Physiol. 2021;320(1):H13–H33
19.Turakulov R.I., Sayfullayev M.B., Gadayeva N.A. Features of differential diagnosis of anemia of chronic disease and iron de ficiency anemia Comorbidities in chronic heart failure // Chal lenges in science of nowadays. – 2020. – С. 26-28..